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To the Editor: In his recent in-depth review of cholesterol
crystal embolization syndrome (CCE), Meyrier1 has deli-
neated the pathogenesis, differential diagnoses, and thera-
peutic aspects of CCE. In addition to therapeutic measures of
paramount importance such as restriction of further
intravascular interventions, stop of anticoagulation, and
treatment of renal insufficiency with dialysis, we would
like to add the possibility of performing renal transplantation
in selected CCE cases with end-stage renal disease and
stable clinical course after diagnosis of CCE. We have
previously reported a patient with CCE successfully under-
going renal transplantation.2 According to the best of our
knowledge, there are so far no other published cases of the
renal transplantation after CCE-induced end-stage renal
disease.
Briefly, a 63-year-old patient with a high load of
atherosclerotic risk factors (heavy smoker, hypertension
160/80–180/100 mm Hg, severe hyperlipidemia (triglycerides
up to 500 mg/dl; low-density lipoprotein cholesterol up to
240 mg/dl)) suffered from end-stage renal disease owing to
cholesterol emboli after coronary angiography because of
symptomatic coronary artery disease in October 1997.
Within 1 week, the patient developed renal failure necessitat-
ing hemodialysis since December 1997. Smoking cessation,
effective control of blood pressure (o130/80 mm Hg), and
serum lipids (low-density lipoprotein cholesterol o100 mg/
dl) was achieved and maintained until successful renal
transplantation from a living related donor in 1998. Until
his last follow-up in May 2006, kidney function has remained
stable with a current serum creatinine level of 1.28 mg/dl,
corresponding to a calculated creatinine clearance of 60 ml/
min. Serum lipids have remained normalized with diet and
pravastatin therapy (40 mg/day) with total cholesterol levels
of about 187 mg/dl and low-density lipoprotein cholesterol
levels of about 120 mg/dl as well as normotensive blood
pressure levels have been achieved with losartan, doxazosin,
nitrendipin, and nebivolol combined antihypertensive ther-
apy, and the patient refrained from smoking.
In conclusion, secondary prevention of CCE, that is, rigid
long-term control of the underlying atherosclerotic risk
factors may enable a selected subgroup of patients with CCE
to undergo successful renal transplantation with excellent
long-term patient and graft survival.
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Kryvoshey et al.’s experience1 with renal transplantation to
treat end-stage renal disease following cholesterol crystal
embolism to the kidney is quite interesting. That renal
replacement was not complicated by relapse of cholesterol
crystal embolism on the transplant confirms the interest of
stabilizing atherosclerotic plaques with statins, as already
shown by Scolari et al.2 However, patients with massive
cholesterol crystal embolism do not die from renal failure
but from vital organ injury, such as mesenteric and
pancreatic ischemia. From this standpoint, the writers of
this letter confirm the essential role of preventing
cholesterol crystal embolism in patients at risk, that is,
lifelong smokers with lipid disorders and widespread
atherosclerosis.
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To the Editor: We were interested in the recent paper by
Kanderian and Francis1 in which they review hypothetical
mechanisms contributing to the increase in serum troponin
concentrations observed in chronic kidney disease (CKD).
The work of Diris et al.,2 who demonstrated fragments of the
cardiac troponin T (cTnT) molecule ranging in size from 8 to
25 kDa in hemodialysis patients, is discussed. It is suggested
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that these fragments, which would normally be small enough
to be cleared by glomerular filtration, accumulate in the
circulation of patients with end-stage renal disease and
crossreact in immunoassays for cTnT.
Recent evidence, unavailable to Kanderian and Francis
when their paper was accepted, argues against this. Firstly,
cTnT concentrations are significantly increased among
patients with CKD long before end stage is reached
(i.e. when significant glomerular filtration remains).3
Secondly, using a direct gel-filtration chromatography
approach, we have shown that the form of cTnT circulating
in dialysis patients and reacting in the commercial cTnT
immunoassay is an intact, free form, identical in size to that
observed among non-CKD patients following an acute
coronary syndrome, with no evidence of smaller molecular
weight fragments.4 Diris et al.2 used a complex analytical
approach including the use of Western blotting, which is
known to be susceptible to artifact.
Much work is needed before the pathophysiology under-
lying cardiac troponin increases in CKD is fully understood.
However, it is important that this presentation is not
dismissed as an artifact due to fragment accumulation:
increases in CKD are real and predict death.
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We thank Lamb et al.1 for bringing to our attention new
data regarding the mechanism of elevated circulating
troponin levels (cTnT) in patients with renal dysfunction.
We were unaware of their recently published results. Their
work indicates that it is the free-form cTnT that is being
measured in patients with chronic kidney disease (CKD),
identical in size to that of cTnT observed in non-renal
disease patients, and not a smaller fragment of cTnT as
suggested earlier by Diris et al.2 We agree that although the
mechanism of altered cTnT levels in CKD is not fully
understood, increased cTnT levels are consistently asso-
ciated with an incremental change in morbidity and
mortality, and cannot be dismissed as laboratory artifact.
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To the Editor: Little et al.1 recently analyzed post-
transplantation recurrence risk in patients with membrano-
proliferative glomerulonephritis (MPGN). They found that
age and crescents on initial biopsy determined this risk rather
than the type of MPGN. The authors suggest that type II
MPGN may not be very different from type I MPGN.
However, it is evident that type I and II MPGN are
pathologically and pathogenetically different entities. Like-
wise, membranous nephropathy and focal segmental glomer-
ulosclerosis are totally different diseases, although the
nephrotic syndrome rather than the diagnosis determines
outcome. Crescents may be a common risk factor for
recurrent disease, as has been suggested for immunoglobulin
A-nephropathy.2 From the data we cannot retrieve if clinically
silent recurrences of type II MPGN have been missed.
Furthermore, the multivariate analysis did not include
potential risk factors as repeated transplantation and living-
related donor transplantation.3 In our single-center studies,
we noted significant differences between type I and II MPGN
with regard to post-transplant recurrence. A recurrence of
type I MPGN occurred in almost 50% of recipients and was
invariably accompanied by clinically significant proteinuria.
Increased risk of recurrence was observed with human
lymphocyte antigen-identical living-related donor kidneys,
the human lymphocyte antigen-B8DR3 haplotype, and
repeated transplants.3 In contrast, all patients with type II
MPGN who had been biopsied (11 of 13) showed a
recurrence. Most recurrences were, however, clinically silent
and required immunofluorescence or electron microscopy for
diagnosis. Still, patients with type II MPGN had poor graft
survival. Crescents in the original biopsy were not specific
predictors.4
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